Medtronic Hugo™ Robotic-Assisted Surgery System Cornerstone of New Robotics Program in Latin America

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the integration of the Hugo™ robotic-assisted surgery (RAS) system at Hospital Clinico de la Red de Salud UC CHRISTUS in Santiago, Chile, to support the teaching institution’s new robotic surgery program. UC CHRISTUS is the latest institution to join Medtronic’s Partners in Possibility Program, a group of pioneering hospitals that will be among the first in the world to use the Hugo RAS system in support of the Hugo system patient registry.

“Our surgical robotics vision — to expand access to quality care to more people in more places — is coming to life at UC CHRISTUS,” said Carla Peron, M.D., chief medical officer of the Surgical Robotics business, which is part of the Medical Surgical Portfolio at Medtronic. “It’s incredibly exciting to see our teams working together to bring surgical robotics where it couldn’t exist before, all for the benefit of patients.”

In Latin America, approximately 75% of surgeries are conducted as open procedures.1 With minimally invasive surgery, those patients could experience fewer complications, shorter hospital stays, faster return to normal activities, and smaller scars.2–4,†,‡

Robotic surgery is a form of minimally invasive surgery that offers surgeons improved visualization, greater dexterity, and ergonomic advantages, yet robots are used in less than 3% of surgeries globally.1 The Hugo RAS system — Medtronic’s solution to historic cost and utilization barriers that have kept surgical robotics out of reach for many hospitals — is a modular, multi-quadrant platform designed for a broad range of soft-tissue procedures.

The Hugo RAS system combines the precision of wristed instruments with the flexibility of independent robotic arm carts and best-in-class 3D visualization technology on an open console. Touch Surgery™ Enterprise, a cloud-based surgical video capture option powered by artificial intelligence, allows surgeons to seamlessly record, analyze, and share Hugo system case footage.

“I am honored to have performed the inaugural robotic-assisted surgery procedure for UC CHRISTUS and to be leading this program, the first of its kind for our institution,” said Ignacio San Francisco, M.D., urological surgeon and specialist in minimally invasive uro-oncology surgery. “With Hugo RAS system, we are entering a new era of robotic-assisted surgery, improving how we deliver high quality healthcare to our patients.”

In support of its commitment to expand access to quality care, Medtronic has opened a new Surgical Robotics Experience Center in Santiago. This is the company’s first in Latin America and 1 of 10 world-class facilities around the globe where clinicians can experience and train on the Hugo RAS system. The Santiago Surgical Robotics Experience Center operates in partnership with the Faculty of Medicine of Pontificia Universidad Católica de Chile, which is affiliated with UC CHRISTUS.

“We are confident that our new robotic surgery program is ready for success and will provide our patients with leading-edge quality healthcare, thanks to the novel capabilities of the Hugo RAS system, the support we have received from our partners at Medtronic, and our outstanding surgeons,” said Alejandro Canavati, chief executive officer, Red de Salud UC CHRISTUS. “As a teaching institution, we are proud to serve as a premier destination for world-class surgical robotics training for physicians across the region.”

The Hugo RAS system is not cleared or approved in the U.S. or Europe. Regulatory requirements of individual countries and regions will determine availability and approval or clearance timelines. Touch Surgery Enterprise is not intended to direct surgery, or aid in diagnosis or treatment of a disease or condition.


†Compared to open surgery.
‡MIS may not be suitable for every patient; consult your doctor to determine if MIS is an option for you.
1. Based on Medtronic report, FY20 market model: procedural volume data.
2. Fitch K, Engel T, Bochner A. Cost differences between open and minimally invasive surgery. Managed Care. 2015 Sep;24(9):40–48.
3. Tiwari MM, Reynoso JF, High R, Tsang AW, Oleynikov D. Safety, efficacy, and cost effectiveness of common laparoscopic procedures. Surg Endosc. 2011;25(4):1127–1135.
4. Roumm AR, Pizzi L, Goldfarb NI, Cohn H. Minimally invasive: minimally reimbursed? An examination of six laparoscopic surgical procedures. Surg Innovation.2005;12(3):261–287.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”